TY - JOUR
T1 - Optimizing the management of patients with spinal myeloma disease
AU - UK Spinal Myeloma Working Group
AU - Molloy, Sean
AU - Lai, Maggie
AU - Pratt, Guy
AU - Ramasamy, Karthik
AU - Wilson, David
AU - Quraishi, Nasir
AU - Auger, Martin
AU - Cumming, David
AU - Punekar, Maqsood
AU - Quinn, Michael
AU - Ademonkun, Debo
AU - Willis, Fenella
AU - Tighe, Jane
AU - Cook, Gordon
AU - Stirling, Alistair
AU - Bishop, Timothy
AU - Williams, Cathy
AU - Boszczyk, Bronek
AU - Reynolds, Jeremy
AU - Grainger, Mel
AU - Craig, Niall
AU - Hamilton, Alastair
AU - Chalmers, Isobel
AU - Ahmedzai, Sam
AU - Selvadurai, Susanne
AU - Low, Eric
AU - Kyriakou, Charalampia
N1 - © 2015 John Wiley & Sons Ltd.
PY - 2015/11
Y1 - 2015/11
N2 - Myeloma is one of the most common malignancies that results in osteolytic lesions of the spine. Complications, including pathological fractures of the vertebrae and spinal cord compression, may cause severe pain, deformity and neurological sequelae. They may also have significant consequences for quality of life and prognosis for patients. For patients with known or newly diagnosed myeloma presenting with persistent back or radicular pain/weakness, early diagnosis of spinal myeloma disease is therefore essential to treat and prevent further deterioration. Magnetic resonance imaging is the initial imaging modality of choice for the evaluation of spinal disease. Treatment of the underlying malignancy with systemic chemotherapy together with supportive bisphosphonate treatment reduces further vertebral damage. Additional interventions such as cement augmentation, radiotherapy, or surgery are often necessary to prevent, treat and control spinal complications. However, optimal management is dependent on the individual nature of the spinal involvement and requires careful assessment and appropriate intervention throughout. This article reviews the treatment and management options for spinal myeloma disease and highlights the value of defined pathways to enable the proper management of patients affected by it.
AB - Myeloma is one of the most common malignancies that results in osteolytic lesions of the spine. Complications, including pathological fractures of the vertebrae and spinal cord compression, may cause severe pain, deformity and neurological sequelae. They may also have significant consequences for quality of life and prognosis for patients. For patients with known or newly diagnosed myeloma presenting with persistent back or radicular pain/weakness, early diagnosis of spinal myeloma disease is therefore essential to treat and prevent further deterioration. Magnetic resonance imaging is the initial imaging modality of choice for the evaluation of spinal disease. Treatment of the underlying malignancy with systemic chemotherapy together with supportive bisphosphonate treatment reduces further vertebral damage. Additional interventions such as cement augmentation, radiotherapy, or surgery are often necessary to prevent, treat and control spinal complications. However, optimal management is dependent on the individual nature of the spinal involvement and requires careful assessment and appropriate intervention throughout. This article reviews the treatment and management options for spinal myeloma disease and highlights the value of defined pathways to enable the proper management of patients affected by it.
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Diphosphonates/therapeutic use
KW - Female
KW - Humans
KW - Magnetic Resonance Imaging
KW - Male
KW - Multiple Myeloma/diagnostic imaging
KW - Radiography
KW - Spinal Neoplasms/diagnostic imaging
U2 - 10.1111/bjh.13577
DO - 10.1111/bjh.13577
M3 - Article (Academic Journal)
C2 - 26184699
SN - 0007-1048
VL - 171
SP - 332
EP - 343
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -